Media

Media Contact National Headquarters Walmart & FAACT Take the Fear Out of Halloween Fun! FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal Epinephrine) Pulmonary-Allergy Drugs Advisory Committee Meeting DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut FAACT Partners with MenuTrinfo® FAACT Is Learning to Live in Empathy A Statement from the Food Allergy & Anaphylaxis Connection Team about Racism, Food Allergy Disparities, and Health Inequities FAACT, ACAAI, NPB Partner on Early Intro to Peanut Vitality Bowls Rallies Communities in Support of Food Allergy Awareness Global Parenting Expert, Jo Frost, Announced as National Spokesperson for FAACT and Will Raise Awareness Around Food Allergies FAACT CEO Hosts Healthline’s Patient Roundtable: Living with Severe Allergies New FAACT and ACAAI Campaign Seeks to Close the Gap on Food Allergy Diagnosis and Management Awareness FAACT CEO Inducted into NAPW VIP Professional Woman of the Year Circle FAACT CEO Named Among The 15 Most Imporant Moms In the Food Industry FAACT Reaches Clawson Public Schools in Michigan

May 11, 2023

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drug Advisory Committee (PADAC) voted 16:6 in favor for adults, and 17:5 in favor for children (<18 years of age and ≥30 kg), that available data support a favorable benefit-risk assessment for neffy in the treatment of severe allergic reaction (Type 1), including anaphylaxis, for adults and children who weigh more than 30kg. If approved, it could be available in the second half of 2023.

Visit ARS-Pharma to learn more.

Media Contact:
Laura O'Neill
FINN Partners
laura.oneill@finnpartners.com